BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 24631740)

  • 21. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
    Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
    Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission.
    Zhao XS; Qin YZ; Liu YR; Chang YJ; Xu LP; Zhang XH; Huang XJ
    Leuk Lymphoma; 2017 May; 58(5):1135-1143. PubMed ID: 27733089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Characteristics and prognosis in adult acute myeloid leukemia patients with MLL gene rearrangements].
    Gong XY; Wang Y; Liu BC; Wei H; Li CW; Li QH; Zhao JW; Zhou CL; Lin D; Liu KQ; Wei SN; Gong BF; Zhang GJ; Liu YT; Zhao XL; Li Y; Gu RX; Qiu SW; Mi YC; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jan; 39(1):9-14. PubMed ID: 29551026
    [No Abstract]   [Full Text] [Related]  

  • 24. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
    Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of minimal residual disease monitoring by multiparameter flow cytometry pre-conditioning on prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Lu Y; Wu T; Wang H; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Ji SQ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):118-123. PubMed ID: 28279035
    [No Abstract]   [Full Text] [Related]  

  • 27. Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Mo XD; Qin YZ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Ann Hematol; 2016 Aug; 95(8):1233-40. PubMed ID: 27302479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia.
    Koh K; Tomizawa D; Moriya Saito A; Watanabe T; Miyamura T; Hirayama M; Takahashi Y; Ogawa A; Kato K; Sugita K; Sato T; Deguchi T; Hayashi Y; Takita J; Takeshita Y; Tsurusawa M; Horibe K; Mizutani S; Ishii E
    Leukemia; 2015 Feb; 29(2):290-6. PubMed ID: 24888273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
    Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
    Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of WT1 and multiparameter flow cytometry assessment in patients with chronic myelomonocytic leukemia receiving allogeneic hematopoietic stem cell transplantation.
    Pan X; Gao M; Sun Y; Zhou Y; Wang K; Wang Y; Xu L; Zhang X; Huang X; Zhao XS
    Int J Lab Hematol; 2022 Jun; 44(3):510-517. PubMed ID: 35061336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation.
    Zhao X; Wang Z; Ruan G; Liu Y; Wang Y; Zhang X; Xu L; Huang X; Chang Y
    Ann Hematol; 2018 Jun; 97(6):967-975. PubMed ID: 29423758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The effect of WT1 expression on the prognosis of allogeneic hematopoietic stem cell transplantation in acute leukemia].
    Jiang BQ; Luo Y; Zhao YM; Tan YM; Yu J; Lai XY; Zhu YY; Sun J; Zheng WY; He JS; Wei GQ; Cai Z; Huang H; Shi JM
    Zhonghua Xue Ye Xue Za Zhi; 2018 Dec; 39(12):989-993. PubMed ID: 30612399
    [No Abstract]   [Full Text] [Related]  

  • 33. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study.
    Mann G; Attarbaschi A; Schrappe M; De Lorenzo P; Peters C; Hann I; De Rossi G; Felice M; Lausen B; Leblanc T; Szczepanski T; Ferster A; Janka-Schaub G; Rubnitz J; Silverman LB; Stary J; Campbell M; Li CK; Suppiah R; Biondi A; Vora A; Valsecchi MG; Pieters R;
    Blood; 2010 Oct; 116(15):2644-50. PubMed ID: 20592248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes of allogeneic haematopoietic stem cell transplantation for paediatric patients with MLL-rearranged acute myeloid leukaemia.
    Bai L; Zhang YZ; Yan CH; Wang Y; Xu LP; Zhang XH; Zhang LP; Huang XJ; Cheng YF
    BMC Cancer; 2022 Aug; 22(1):896. PubMed ID: 35974319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Leukemia: 25 Years' Experience at Gustave Roussy Cancer Campus.
    Chamseddine AN; Willekens C; De Botton S; Bourhis JH
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S129-40. PubMed ID: 26297265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
    Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation.
    Ino K; Fuji S; Tajima K; Tanaka T; Okinaka K; Inamoto Y; Kurosawa S; Kim SW; Katayama N; Fukuda T
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1780-1787. PubMed ID: 28673850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. WT1 Gene Expression in Peripheral Blood Before and After Allogeneic Stem Cell Transplantation is a Clinically Relevant Prognostic Marker in AML - A Single-center 14-year Experience.
    Valkova V; Vydra J; Markova M; Cerovska E; Vrana M; Marinov I; Cechova H; Cetkovsky P; Vitek A; Salek C
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e145-e151. PubMed ID: 33160932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
    Rossi G; Carella AM; Minervini MM; Savino L; Fontana A; Pellegrini F; Greco MM; Merla E; Quarta G; Loseto G; Capalbo S; Palumbo G; Cascavilla N
    Leuk Lymphoma; 2013 Dec; 54(12):2660-6. PubMed ID: 23547840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.